Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers

Molecular Therapy

Volumn 20, Issue 1, 2012, Pages 54-62

  Puig Saus, Cristina ^a   Gros, Alena ^a   Alemany, Ramon ^a   Cascalló, Manel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS;

ADENOVIRUS 5; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; GAIN OF FUNCTION MUTATION; GENE SEQUENCE; GENETIC SELECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MALE; MOUSE; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHENOTYPE; SINGLE DRUG DOSE; STROMA CELL; VIRUS MUTATION; VIRUS RELEASE; WILD TYPE;

ADENOVIRIDAE; MUS;

EID: 84860395763     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.159     Document Type: Article

References (44)

1. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
2. Strauss, R and Lieber, A (2009). Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. Curr Opin Mol Ther 11: 513-522.
3. Liu, TC, Hwang, TH, Bell, JC and Kirn, DH (2008). Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop. Mol Ther 16: 1006-1008. (Pubitemid 351737062)
4. Kalluri, R and Zeisberg, M (2006). Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
5. Micke, P and Ostman, A (2005). Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9: 1217-1233. (Pubitemid 41762875)
6. Lopez, MV, Viale, DL, Cafferata, EG, Bravo, AI, Carbone, C, Gould, D et al. (2009). Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses. PLoS ONE 4: e5119.
7. Sauthoff, H, Hu, J, Maca, C, Goldman, M, Heitner, S, Yee, H et al. (2003). Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 14: 425-433. (Pubitemid 36403535)
8. Wein, LM, Wu, JT and Kirn, DH (2003). Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 63: 1317-1324. (Pubitemid 36348711)
9. Paiva, LR, Binny, C, Ferreira, SC Jr and Martins, ML (2009). A multiscale mathematical model for oncolytic virotherapy. Cancer Res 69: 1205-1211.
10. Lamont, JP, Nemunaitis, J, Kuhn, JA, Landers, SA and McCarty, TM (2000). A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 7: 588-592.
11. Alonso, MM, Gomez-Manzano, C, Jiang, H, Bekele, NB, Piao, Y, Yung, WK et al. (2007). Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14: 756-761. (Pubitemid 47080367)
12. Gros, A, Puig, C, Guedan, S, Rojas, JJ, Alemany, R and Cascallo, M (2010). Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol Ther 18: 903-911.
13. Ganesh, S, Gonzalez Edick, M, Idamakanti, N, Abramova, M, Vanroey, M, Robinson, M et al. (2007). Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 67: 4399-4407. (Pubitemid 46815089)
14. Guedan, S, Rojas, JJ, Gros, A, Mercade, E, Cascallo, M and Alemany, R (2010). Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 18: 1275-1283.
15. Yamamoto, M and Curiel, DT (2010). Current issues and future directions of oncolytic adenoviruses. Mol Ther 18: 243-250.
16. Liu, TC, Hallden, G, Wang, Y, Brooks, G, Francis, J, Lemoine, N et al. (2004). An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factorenhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 9: 786-803. (Pubitemid 38878125)
17. Doronin, K, Toth, K, Kuppuswamy, M, Ward, P, Tollefson, AE and Wold, WS (2000). Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 74: 6147-6155. (Pubitemid 30412986)
18. Gros, A, Martiez-Quintanilla, J, Puig, C, Guedan, S, Molleví DG, Alemany, R et al. (2008). Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res 68: 8928-8937.
19. Yan, W, Kitzes, G, Dormishian, F, Hawkins, L, Sampson-Johannes, A, Watanabe, J et al. (2003). Developing novel oncolytic adenoviruses through bioselection. J Virol 77: 2640-2650. (Pubitemid 36222789)
20. Subramanian, T, Vijayalingam, S and Chinnadurai, G (2006). Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 80: 2000-2012. (Pubitemid 43228740)
21. Stoff, A, Rivera, AA, Banerjee, NS, Mathis, JM, Espinosa-de-los-Monteros, A, Le, LP et al. (2006). Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds. Wound Repair Regen 14: 608-617. (Pubitemid 44470079)
22. Suzuki, K, Fueyo, J, Krasnykh, V, Reynolds, PN, Curiel, DT and Alemany, R (2001). A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7: 120-126. (Pubitemid 32110214)
23. Williams, JF, Gharpure, M, Ustacelebi, S and McDonald, S (1971). Isolation of temperature-sensitive mutants of adenovirus type 5. J Gen Virol 11: 95-101.
24. Pilder, S, Logan, J and Shenk, T (1984). Deletion of the gene encoding the adenovirus 5 early region 1b 21,000-molecular-weight polypeptide leads to degradation of viral and host cell DNA. J Virol 52: 664-671. (Pubitemid 15200219)
25. Parrott, JA, Nilsson, E, Mosher, R, Magrane, G, Albertson, D, Pinkel, D et al. (2001). Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Mol Cell Endocrinol 175: 29-39. (Pubitemid 32372541)
26. Gros A, Guedan S (2010). Adenovirus release from the infected cell as a key factor for adenovirus oncolysis. The Open Gene Therapy Journal 3: 24-30.
27. Wenger, C, Ellenrieder, V, Alber, B, Lacher, U, Menke, A, Hameister, H et al. (1999). Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 18: 1073-1080. (Pubitemid 29086285)
28. Soloway, PD and Shenk, T (1990). The adenovirus type 5 i-leader open reading frame functions in cis to reduce the half-life of L1 mRNAs. J Virol 64: 551-558. (Pubitemid 20032665)
29. Symington, JS, Lucher, LA, Brackmann, KH, Virtanen, A, Pettersson, U and Green, M (1986). Biosynthesis of adenovirus type 2 i-leader protein. J Virol 57: 848-856. (Pubitemid 16143965)
30. Tollefson, AE, Scaria, A, Hermiston, TW, Ryerse, JS, Wold, LJ and Wold, WS (1996). The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 70: 2296-2306. (Pubitemid 26087592)
31. Ramachandra, M, Rahman, A, Zou, A, Vaillancourt, M, Howe, JA, Antelman, D et al. (2001). Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 19: 1035-1041. (Pubitemid 33041887)
32. Sauthoff, H, Heitner, S, Rom, WN and Hay, JG (2000). Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 11: 379-388. (Pubitemid 30101948)
33. van Beusechem, VW, van den Doel, PB, Grill, J, Pinedo, HM and Gerritsen, WR (2002). Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 62: 6165-6171. (Pubitemid 35244467)
34. Wodarz, D (2001). Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res 61: 3501-3507. (Pubitemid 32695047)
35. Alemany, R and Cascallo, M (2009). Oncolytic viruses from the perspective of the immune system. Future Microbiol 4: 527-536.
36. Yun, CO, Kim, E, Koo, T, Kim, H, Lee, YS and Kim, JH (2005). ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 12: 61-71. (Pubitemid 39665244)
37. Tollefson, AE, Scaria, A, Ying, B and Wold, WS (2003). Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells. J Virol 77: 7764-7778. (Pubitemid 36792773)
38. Wang, Y, Hallden, G, Hill, R, Anand, A, Liu, TC, Francis, J et al. (2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21: 1328-1335. (Pubitemid 37356618)
39. Bortolanza, S, Bunuales, M, Alzuguren, P, Lamas, O, Aldabe, R, Prieto, J et al. (2009). Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters. Cancer Gene Ther 16: 703-712.
40. Rojas, JJ, Guedan, S, Searle, PF, Martinez-Quintanilla, J, Gil-Hoyos, R, Alcayaga-Miranda, F et al. (2010). Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther 18: 1960-1971.
41. Molleví DG, Aytes, A, Berdiel, M, Padull, L, Martiez-Iniesta, M, Sanjuan, X et al. (2009). PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts. Mol Cancer 8: 46.
42. Dmitriev, I, Krasnykh, V, Miller, CR, Wang, M, Kashentseva, E, Mikheeva, G et al. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72: 9706-9713. (Pubitemid 28520834)
43. Alemany, R and Curiel, DT (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 8: 1347-1353. (Pubitemid 32834304)
44. Cascallo, M, Gros, A, Bayo, N, Serrano, T, Capella, G and Alemany, R (2006). Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses. Hum Gene Ther 17: 929-940. (Pubitemid 46076753)